Management and therapy of dry eye disease: Report of the management and therapy subcommittee of the international Dry Eye WorkShop (2007)

Ocular Surface

Volumn 5, Issue 2, 2007, Pages 163-178

  Pflugfelder, Stephen C ^a   Geerling, Gerd ^b   Kinoshita, Shigero ^b   Lemp, Michael A ^b   McCulley, James ^b   Nelson, Daniel ^b   Novack, Gary N ^b   Shimazaki, Jun ^b   Wilson, Clive ^b  

^a CULLEN EYE INSTITUTE   (United States)

^b NONE

Author keywords

DEWS; Dry eye disease; Dry Eye WorkShop; Management; Therapy

Indexed keywords

12 SULFODEHYDROABIETIC ACID; 15 HYDROXYICOSATETRAENOIC ACID; ANDROGEN; ANGIOGENESIS INHIBITOR; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ARTIFICIAL TEAR; BENZALKONIUM CHLORIDE; CEVIMELINE; CORTICOSTEROID; CYCLOSPORIN A; DE 089; DIQUAFOSOL; DOXYCYCLINE; DWELLE; EDETIC ACID; ENDURA; ESSENTIAL FATTY ACID; FLUOROMETHOLONE; FLURBIPROFEN; GEFARNATE; GENTEAL; HYPOTEARS; HYPOTEARS PF; LOTEPREDNOL ETABONATE; METHYLPREDNISOLONE; MINOCYCLINE; OPTIVE; PILOCARPINE; PLACEBO; REBAMIPIDE; REFRESH; REFRESH FREE; SOOTHE; SYSTANE; TACROLIMUS; TEARS NATURAL FREE; TESTOSTERONE; TETRACYCLINE DERIVATIVE; TETRYZOLINE; THERATEARS; UNINDEXED DRUG; VISINE PURE TEARS; ELECTROLYTE; EYE DROPS; PRESERVATIVE;

ABSENCE OF SIDE EFFECTS; AUTOTRANSPLANTATION; BLEPHARITIS; BURNING SENSATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTACT LENS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; EYE DISEASE; HUMAN; HYPERHIDROSIS; KERATOCONJUNCTIVITIS SICCA; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; OSMOLARITY; RHEUMATOID ARTHRITIS; ROSACEA; SALIVARY GLAND; SCHIRMER TEST; SJOEGREN SYNDROME; SYSTEMIC DISEASE; TEAR FILM; UNSPECIFIED SIDE EFFECT; ANIMAL; EVIDENCE BASED MEDICINE; LACRIMAL DUCT; LACRIMAL FLUID; LUBRICATION; METABOLISM; PROSTHESES AND ORTHOSES; REVIEW; SECRETION; VISCOSITY;

ANIMALS; DRY EYE SYNDROMES; ELECTROLYTES; EVIDENCE-BASED MEDICINE; HUMANS; LUBRICATION; NASOLACRIMAL DUCT; OPHTHALMIC SOLUTIONS; OSMOLAR CONCENTRATION; PRESERVATIVES, PHARMACEUTICAL; PROSTHESES AND IMPLANTS; TEARS; VISCOSITY;

EID: 34347229411     PISSN: 15420124     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1542-0124(12)70085-x     Document Type: Conference Paper

References (185)

1. Gilbard JP, Rossi SR, Heyda KG. Ophthalmic solutions, the ocular surface, and a unique therapeutic artificial tear formulation. Am J Ophthalmol 1989;107:348-55
2. Gilhard JP. Human tear film electrolyte concentrations in health and dry-eye disease. Int Ophthalmol Clin 1994;34:27-36
3. Schein O, Tielsch J, Munoz B, et al. Relation between signs and symptoms of dry eye in the elderly. Ophthalmology 1997;104:1395-1400 (CS2)
4. Nelson JD, Gordon JF. Topical fibronectin in the treatment of keratoconjunctivitis sicca. Chiron Keratoconjunctivitis Sicca Study Group. Am J Ophthalmol 1992;114:441-7
5. Nelson JD. Impression cytology. Cornea 1988;7:71-81
6. Ubels J, McCartney M, Lantz W, et al. Effects of preservative-free artificial tear solutions on corneal epithelial structure and function. Arch Ophthalmol 1995;113:371-8
7. Green K, MacKeen DL, Slagle T, Checks L. Tear potassium contributes to maintenance of corneal thickness. Ophthalmic Res 1992;24:99-102
8. Holly F, Lemp M. Surface chemistry of the tear film: Implications for dry eye syndromes, contact lenses, and ophthalmic polymers. Contact Lens Soc Am J 1971;5:12-9
9. Perrigan DM, Morgan A, Quintero S, et al. Comparison of osmolarity values of selected ocular lubricants. ARVO 2004 poster session 449
10. Kauftnam B, Novack GD. Compliance issues in manufacturing of drugs. Ocul Surf 2003;1:80-5
11. Albietz J, Bruce A. The conjunctival epithelium in dry eye subtypes: Effect of preserved and nonpreserved topical treatments. Curr Eye Res 2001;22:8-18
12. Gasset AR, Ishii Y, Kaufman H, Miller T. Cytotoxicity of ophthalmic preservatives. Am J Ophthalmol 1974;78:98-105
13. Wilson F. Adverse external effects of topical ophthalmic medications. Surv Ophthalmol 1979;24:57-88
14. Burstein N. Corneal cytotoxicity of topically applied drugs, vehicles and preservatives. Surv Ophthalmol 1980;25:15-30
15. Burstein N. The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye. Trans Ophthalmol Soc UK. 1985;104:402-9
16. Brubaker R, McLaren J. Uses of the fluorophotometer in glaucoma research. Ophthalmology 1985;92:884-90
17. Smith L, George M, Berdy G, Abelson M. Comparative effect of preservative free tear substitutes on the rabbit cornea: a scanning electron microscopic evaluation (ARVO Abstract). Invest Ophathalmol Vis Sci 1991,32 (Suppl):733
18. Gilbard JP. Farris RL, Santamaria J 2nd. Osmolarity of tear microvolumes in keratoconjunctivitis sicca. Arch Ophthalmol 1978;96:677-81
19. Lopez Bernal D, Ubels JL. Quantitative evaluation of the corneal epithelial barrier effect of airtificial tears and preservatives. Curr Eye Res 1991:10:645-56
20. Bernal DL, Ubels JL. Artificial tear composition and promotion of recovery of the damaged corneal epithelium. Cornea 1993;12:115-20
21. Noecker R: Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001;18:205-15
22. Tripathi BJ, Tripathi RC, Kolli SP: Cytotoxicity of ophthalmic preservatives on human corneal epithelium. Lens Eye Toxicity Res 1992;9:361-75
23. Herrema J, Friedenwald J. Retardation of wound healing in the corneal epithelium by lanolin. Am J Ophthalmol 1950;33:1421
24. Nelson J, Drake M, Brewer J, Tuley M. Evaluation of physiologic tear substitute in patients with keratoconjunctivitis sicca. Adv Exp Med Biol 1994;350:453-7
25. Gilbard JP, Rossi SR. An electrolyte-based solution that increases corneal glycogen and conjunctival goblet-cell density in a rabbit model for keratoconjunctivitis sicca. Ophthalmology 1992;99:600-4
26. Lenton LM, Albietz JM: Effect of carmellose-based artificial tears on the ocular surface in eyes after laser in situ keratomileusis. J Refract Surg 1999;15(2 Suppl):S227-S231
27. Slomiany BL, Slomiany A. Role of mucus in gastric mucosal protection. J Physiol Pharmacol 1991; 42:147-61
28. Gilbard JP. Tear film osmolarity and keratoconjunctivitis sicca. CLAO J 1985;11:243-50
29. Gilbard J. Tear film osmolarity and keratoconjuncitivitis sicca. Lubbock TX,Dry Eye Institute, 1986
30. Gilbard J, Carter J, Sang D, et al. Morphologic effect of hyperosmolarity on rabbit corneal epithelium. Ophthalmology 1984;91:1205-12
31. Luo L, Li D, Corrales R, Pflugfelder S. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Contact Lens 2005;31:186-93
32. Gilbard JP, Kenyon KR. Tear diluents in the trearment of keratoconjunctivitis sicca. Ophthalmology 1985;92:646-50
33. Holly F, Esquivel E. Colloid osmotic pressure of artificial tears. J Ocul Pharmacol 1985;1:327-36
34. Yancey PH: Organic osmolytes as compatible, metabolic and counteracting cryoprotectants in high osmolarity and other stresses. J Exp Biol 2005;208:2819-30
35. Holly F, Lemp M. Wettability and wetting of corneal epithelium. Exp Eye Res 1971;11:239-50
36. Hawi A, Smith T, Digenis G. A quantitiative comparison of artificial tear clearance rates in humans using gamma scintigraphy (ARVO abstract). Invest Ophthalmol Vis Sci 1990;31 (Suppl):517
37. Argueso P, Tisdale A, Spurr-Michaud S, et al. Mucin characteristics of human corneal-limbal epithelial cells that exclude the rose bengal anionic dye. Invest Ophthahmol Vis Sci 2006;47:113-9
38. Versura P, Maltarello M, Stecher F, et al. Dry eye before and after therapy with hydroxypropymethylcellulose. Ophthalmologica 1989;198:152-62
39. Simmons PA, Garrett Q, Xu S, et al. Interaction of carboxymethylcellulose with human corneal cells. ARVO 2006, E-Abstract 2759
40. Christiansen M, Cohen S, Rinehart J, et al. Clinical evaluation of an HP-guar gellable lubricant eye drop for the relief of dryness of the eye. Curr Eye Res 2004;28:55-62
41. Di Pascuale MA, Goto E, Tseng SC. Sequential changes of lipid tear filin after the instillation of a single drop of a new emulsion eye drop in dry eye patients. Ophthalmology 2004; 111: 783-91
42. Korb DR, Scaffidi RC, Greiner JV, et al. The effect of two novel lubricant eye drops on tear film lipid layer thickness in subjects with dry eye symptoms. Optom Vis Sci 2005;82:594-601
43. Snibson GR, Greaves JL, Soper ND, et al. Precorneal residence times of sodium hyaluronate solutions studied by quantitative gamma scintigraphy. Eye 1990;4:594-602
44. Polack F, McNiece M. The treatment of dry eyes with NA hyaluronate (Heaton). Cornea 1982;1:1333
45. Stuart JC, Linn JG. Dilute sodium hyaluronate (Healon) in the treatment of ocular surface disorders. Ann Ophthalmol. 1985;17:190-2
46. DeLuise V, Peterson W. The use of topical Heaton tears in the management of refractory dry-eye syndrome. Ann Ophthalmol 1984; 16:823-4
47. Sand B, Marner K, Norn M. Sodium hyaluronate in the treatment of keratoconjuctivitis sicca. Acta Ophthalmol 1989; 67:181-3
48. Nelson JD, Farris RL. Sodium hyaluronate and polyvinyl alcohol artificial tear preparations a comparison in patients with keratoconjunctivitis sicca. Arch Ophthalmol 1988; 106:484-7
49. Beetham WP. Filamentary keratitis. Trans Am Ophthalmol Soc 1936:33:413-35
50. Foulds WS. Intracanalicular gelatin implants in the treatment of kerato-conjunctivitis sicca. Br J Ophthalmol 1961:45:625-7
51. Freeman JM. The punctum plug: evaluation of a new treatment for the dry eye. Trans Am Acad Ophthalmol Otolaryngol 1975:79:OP874-9
52. Tuberville AW, Frederick WR, Wood TO. Punctal occlusion in tear deficiency syndromes. Ophthalmology 1982;89:1170-2
53. Willis RM, Folberg R, Krachmer JH, et al. The treatment of aqueous-deficient dry eye with removable punctal plugs. A clinical and impression-cytological study. Ophthalmology 1987;94:514-8
54. Gilbard JP, Rossi SR, Azar DT, Gray KL. Effect of punctal occlusion by Freeman silicone plug insertion on tear osmolarity in dry eye disorders. CLAO J 1989;15:216-8
55. Balaram M, Schaumberg DA, Dana MR. Efficacy and tolerability outcomes after punctal-occlusion with silicone plugs in dry eye syndrome. Am J Ophthalmol 2001;131:30-6
56. Baxter SA, Laibson PR. Punctal plugs in the management of dry eyes Ocul Surf 2004:2:255-65
57. Bartlett JD, Boan K, Corliss D, Gaddie IB. Efficacy of silicone punctal plugs as adjuncts to topical pharmacotherapy of glaucoma--a pilot study. Punctal Plugs in Glaucoma Study Group. J Am Optom Assoc 1996;67:664-8
58. Huang TC, Lee DA. Punctal occlusion and topical medications for glaucoma. Am J Ophthalmol 1989;107:151-5
59. Sugita J, Yokoi N, Fullwood NJ, et al. The detection of bacteria and bacterial biofilms in punctal plug holes. Cornea 2001;20: 362-5
60. Gerding H, Kuppers J, Busse H. Symptomatic cicatrizial occlusion of canaliculi after insertion of Herrick lacrimal plugs. Am J Ophthalmol 2003;136:926-8
61. Lee J, Flanagan JC. Complications associated with silicone intracanalicular plugs. Ophthal Plast Reconstr Surg 2001; 17:465-9
62. Paulsen F. The human lacrimal glands. Adv Anat Embryol Cell Biol 2003-170:III-XI,1-106
63. Yen MT, Pflugfelder SC, Feuer WJ. The effect of punctal occlusion on tear production, tear clearance, and ocular surface sensation in normal subjects. Am J Ophthalmol 2001; 131:314-23
64. Tsubota K. The effect of wearing spectacles on the humidity of the eye. Am J Ophthalmol 1989;15;108:92-3
65. Isubota K, Yamada M, Urayama K. Spectacle side panels and moist inserts for the treatment of dry-eye patients. Cornea 1994;13:197-201
66. Gresset J, Simonet P, Gordon D. Combination of a side shield with an ocular moisture chamber. Am J Optom Physiol Opt 1984;61:610-2
67. Savar DE. A new approach to ocular moisture chambers. J Pediatr Ophthalmol Strabismus 1978; 15:51-3
68. Kurihashi K. Moisture aid during sleep for the treatment of dry eye: wet gauze eye mask. Ophthalmologica 1994;208:216-9
69. Nichols JJ, Ziegler C, Mitchell GL, Nichols KK. Self-reported dry eye disease across refractive modalities. Invest Ophthalmol Vis Sci 2005;46:1911-4
70. Korb DR, Greiner JV, Glonek T, et al. Effect of periocular humidity on the tear-film lipid layer. Cornea 1996;15:129-34
71. Tsubota K, Hata S, Okusawa Y, et al. Quantitative videographic analysis of blinking in normal subjects and patients with dry eye. Arch Ophthalmol 1996; 114:715-20
72. Maruyama K, Yokoi N, Takamata A, Kinoshita S. Effect of environmental conditions on tear dynamics in soft contact lens wearers. Invest Ophthalmol Vis Sci 2004;45:2563-8
73. Bacon AS, Astin C, Dart JK. Silicone rubber contact lenses for the compromised cornea. Cornea 1994,13:422-8
74. Pullum KW, Whiting MA, Bluckley RJ. Scleral contact lenses: the expanding role. Cornea 2005;24:269-77
75. Tappin MJ, Pullum KW, Buckley RJ. Scleral contact lenses for overnight wear in the management of ocular surface disorders. Eye 2001:15(Pt 2):168-72
76. Romero-Rangel T, Stavrou F, Cotter J, et al. Gas-permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmol 2000;130:25-32
77. Rosenthal P, Cotter JM, Baum J. Treatment of persistent corneal epithelial defect with extended wear of a fluid-ventilated gas-permeable scleral contact lens. Am J Ophthalmol 2000;130:33-41
78. Tauber J, Davitt WT, Bokosky JE, et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea 2004;23:784-92
79. Mundasad MV, Novack GD, Allgood VE, et al. Ocular safety of INS365 ophthalmic solution: a P2Y(2) agonist in healthy subjects. J Ocul Pharmacol Ther 2001;17:173-9
80. Murakami T, Fujihara T, Horibe Y, Nakamura M. Diquafosol elicits increases in net Cl- transport through P2Y2 receptor stimulation in rabbit. conjunctiva. Ophthalmic Res 2004;36:89-93
81. Li DQ, Lokeshwar BL, Solomon A, et al. Regulation of MMP-9 in human corneal epithelial cells. Exp Eye Res 2001;73:449-59
82. Murakami T, Fujita H, Fujihara T. et al. Novel-noninvasive sensitive determination of tear volume changes in normal cats. Ophthalmic Res 2002;34:371-4
83. Yerxa BR, Mundasad M, Sylvester RN, et al. Ocular safety of INS365 ophthalmic solution, a P2Y2 agonist, in patients with mild to moderate dry eye disease. Adv Exp Med Biol 2002;506(Pt B): 1251-7
84. Fujihara T, Murakami T, Fujita H, et al. Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci 2001;42:96-100
85. Fujihara T, Murakami T, Nagano T, et al. INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model. J Ocul Pharmacol Ther 2002;18:363-70
86. Yerxa BR, Douglass JG, Elena PP et al. Potency and duration of action of synthetic P2Y2 receptor agonists on Schirmer scores in rabbits. Adv Exp Med Biol 2002;506(Pt A):261-5
87. Urashima H, Okamoto T, Takeji Y, et al. Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetyl-cysteine-treated in vivo model. Cornea 2004;23:613-9
88. Tanito M, Takanashi T, Kaidzu S, et al. Cytoprotective effects of rebamipide and carteolol hydrochloride against ultraviolet B-induced corneal damage in mice. Invest Ophthalmol Vis Sci 2003; 44:2980-5
89. Masuda K, Tokushige H, Ogawa T, et al. Effect of topical ecabet sodium on mucin levels in the tear fluid of patients with dry eye. SERI-ARVO2003.
90. Toshida H, Nakata K, Hamano T, et al. Effect of gefarnate on the ocular surface in squirrel monkeys Cornea 2002;21:292-9
91. Nakamura M, Endo K, Nakata K, Hamano T. Gefarnate increases PAS positive cell density in rabbit conjunctiva. Br J Ophthalmol 1998;82:1320-3
92. Nakamura M, Endo K, Nakata K, Hamano T. Gefarnate stimulates secretion of mucin-like glycoproteins by corneal epithelium in vitro and protects corneal epithelium from desiccation in vivo. Exp Eye Res 1997;65:569-74
93. Toshida H, Nakata K, Hamano T, et al. Gefarnate stimulates goblet cell repopulation following an experimental wound to the tarsal conjunctiva in the dry eye rabbit. Adv Exp Med Biol 2002;506(Pt A):353-7
94. Hamano T. Dry eye treatment with eye drops that stimulate mucin production. Adv Exp Med Biol 1998;438:965-8
95. Jumblatt JE, Cunningham L, Jumblatt MM. Effects of 15(S)-HETE on human conjunctival mucin secretion. Adv Exp Med Biol 2002;506(Pt A):323-7
96. Gamache DA, Wei ZY, Weimer LK, et al. Corneal protection by the ocular mucin secretagogue 15(S)-HETE in a rabbit model of desiccation-induced corneal defect. J Ocul Pharmacol Ther 2002;18:349-61
97. Jackson RS 2nd, Van Dyken SJ, McCartney MD, Ubels JL. The eicosanoid, 15-(S)-HETE, stimulates secretion of mucin-like glycoprotein by the conical epithelium Cornea 2001;20:516-21
98. Azar RG, Edelhauser HF. Evaluation of the effects of 15(S)-HETE on corneal epithelial cells: an electrophysiological and cytochemical study. Adv Exp Med Biol 2002; 506(Pt A):329-33
99. Ubels JL, Aupperlee MD, Jackson RS 2nd, et al. Topically applied 15-(S)-HETE stimulates mucin production by corneal epithelium. Adv Exp Med Biol 2002;506(Pt A):317-21
100. Gamache DA, Wei ZY, Weimer LK, et al. Preservation of corneal integrity by the mucin secretagogue 15(S)-HETE in a rabbit model of desiccation-induced dry eye. Adv Exp Med Biol 2002;506(Pt A):335-40
101. Jumblatt JE, Cunningham LT, Li Y, Jumblatt MM. Characterization of human ocular mucin secretion mediated by 15(S)-HETE. Cornea 2002;21:818-24
102. Vivino FB, Al-Hashimi I, Khan K, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren's syndrome. Arch Intern Med 1999;159:174-81
103. Takaya M, Ichikawa Y, Yamada C, et al. Treatment with pilocarpine hydrochloride for sicca symptoms in Sjogren's syndrome. Ryumachi 1997;37:453-7
104. Tsifetaki N, Kitsos G, Paschides CA, et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjogren's syndrome: a randomised 12-week controlled study. Ann Rheum Dis 2003;62:1204-7
105. Papas AS, Sherrer YS, Charney M, et al. Successful treatment of dry mouth and dry eye symptoms in Sjogren's syndrome patients with oral pilocarpine: A randomized, placebo-controlled, dose-adjustment study. J Clin Rheumatol 2004;4:169-77
106. Aragona P, Di Pietro R, Spinella R, Mobrici M. Conjunctival epithelium improvement after systemic pilocarpine in patients with Sjogren's syndrome. Br J Ophthalmol 2006;90:166-70
107. Petrone D, Condemi JJ, Fife R, et al. Double-blind randomized placebo-controlled study of cevimeline in Sjogren's syndrome patients with xerostomia and keratoconjunctivius sicca. Arthritis Rheum 2002;46:748-54
108. Ono M, Takamura E, Shinozaki K, et al. Therapeutic effect of cevimeline on dry eye in patients with Sjogren's syndrome: a randomized, double-blind clinical study. Am J Ophthalmol 2004;138:6-17
109. Geerling G, Daniels JT, Dart JK, et al. Toxicity of natural tear substitutes in a fully defined culture model of human corneal epithelial cells. Invest Ophthalmol Vis Sci 2001;42948-56
110. Geerling G, Honnicke K, Schroder C, et al. Quality of salivary tears following autologous submandibular gland transplantation for severe dry eye. Graefes Arch Clin Exp Ophthalmol 2000;238:45-52
111. Tsubota K, Goto E, Fujita H, et al. Treatment of dry eye by autologous serum application in Sjogren's syndrome. Br J Ophthalmol 1999;83:390-5
112. Geerling G, Hartwig D. Autologous serum eyedrops for ocular surface disorders, in Reinhard T, Larkin F (eds). Cornea and external eye disease. Berlin, Heidelberg, Springer, 2005, pp 2-19
113. Liu L, Hartwig D, Harloff S, et al. An optimised protocol for the production of autologous serum eyedrops. Graefes Arch Clin Exp Ophthalmol 2005;243:706-14
114. Tananuvat, N, Daniell M, Sullivan LJ, et al. Controlled study of the use of autologous serum in dry eye patients. Cornea 2001;20:802-6
115. Kojima T, Ishida R, Dogru M, et al. The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol 2005;139:242-6
116. Noble BA, Loh RS, MacLennan S, et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br J Ophthalmol 2004;88:647-52
117. Noda-Tsuruya T, Asano-Kato N, Toda I, Tsubota K. Autologous serum eye drops for dry eye after LASIK. J Refract Surg 2006;22:61-6
118. Schulze SD, Sekundo W, Kroll P. Autologous serum for the treatment of conical epithelial abrasions in diabetic patients undergoing vitrectomy. Am J Ophthalmol 2006;142:207-11
119. Geerling G, Sieg P, Bastian GO, Laqua H. Transplantation of the autologous submandibular gland for most severe cases of keratoconjunctivitis sicca. Ophthalmology 1998;105:327-35
120. Schroder, Sieg P, Framme C, et al. [Transplantation of the submandibular gland in absolute dry eyes. Effect on the ocular surface]. Klin Monatsbl Augenheilkd 2002;219:494-501
121. Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci 2004;4-5:4293-301
122. Niederkorn JY, Stern ME, Pfluglelder SC, et al. Desiccating stress induces T cell-mediated Sjogren's syndrome-like lacrimal keratoconjunctivitis. J Immunol 2006;176:3950-7
123. Kaswan RE, Salisbury MA, Ward DA. Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops. Arch Ophthalmol 1989;107:1210-16
124. Gunduz K, Ozdemir O. Topical cyclosporin treatment of keraroconjunctivitis sicca in secondary Sjogren's syndrome. Acta Ophthalmol 1994;72:38-42
125. Laibovitz RA, Solch S, Andrianao J. Pilot trial of cyclosporin 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea 1993;12:315-23
126. Steverson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease. A dose-ranging, randomized trial. Ophthalmology 2000;107:967-74
127. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 2000; 107:631-9
128. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol 2002;120:330-7
129. Brignole F, Pisella PJ, De Saint Jean M, et al. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Invest Ophthalmol Vis Sci 2001;42:90-5
130. Turner K, Pfugfelder SC, Ji Z, et al. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea. Cornea 2000;19:492-6
131. Kunert KS, Tisdale AS, Stern ME, Smith JA. Analysis of topical cyclospoire treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol 2000;118:1489-96
132. Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol 2004;138:444-57
133. Avunduk AM, Avunduk MC,Varnell ED, Kaufman HE. The comparison of efficacies of topical corticosteroids and nonsteroidal antiinflammatory drops on dry eye patients: A clinical and immunocytochemical study. Am J Ophthalmol 2003;136:593-602
134. Sainz de la Maza Serra SM, Simon Castellvi C, Kabbani O. Nonpreserved topical steroids and punctal occlusion for severe keratoconjunctivitis sicca. Arch Soc Esp Oftalmol 2000;75:751-56
135. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 1999;106:811-6
136. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004;137:337-42
137. Anonymous. Certain ophthalmic antibiotic combination drugs for human use; Drug efficacy study implementation. Fed Reg 1982;47:21296
138. Anonymous. Certain steroid preparations for ophthalmic and/or otic use. Fed Reg 1980a;45:57776-80
139. Anonymous. Certain ophthalmic antibiotic combination drugs for human use; Drug efficacy study implementation. Fed Reg 1980b;45:57780-3
140. Anonymous. Certain steroid preparation for ophthalmic or otic use. Fed Reg 1976;41:34340-2
141. De Paiva CS, Corrales RM, Villarreal AL, et al. Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. Invest Ophthalmol Vis Sci 2006;47:2847-56
142. De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res 2006;83:526-35
143. Schiffman RM, Bradford R, Bunnell B, et al. A multicenter, double-masked, randomized, vehicle-controlled, parallel-group study to evaluate the safety and efficacy of testosterone ophthalmic solution in pateints with meibomian gland dysfunction. ARVO 2006, E-Abstract 5608
144. Worda C, Nepp J, Huber JC, Sator MO. Treatment of keratoconjunctivitis sicca with topical androgen. Maturitas 2001;37:209-12.
145. Sator MO, Joura EA, Golaszewski T, et al. Treatment of menopausal keratoconjunctivitis sicca with topical oestradiol. Br J Obstet Gynaecol 1998;105:100-2
146. Shine WE, McCulley JP, Pandya AG. Minocycline effect on meibomian gland lipids in meibomianitis patients. Exp Eye Res 2003;76:417-20
147. Dougherty JM, McCulley JP, Silvany RE, et al. The role of tetracycline in chronic hlepharitis, Invest Ophthalmol Vis Sci 1991;32:2970-5
148. Ta CN, Shine WE, McCulley JP, et al. Effects of minocycline on the ocular flora of patients with acne rosacea or seborrheic blepharitis. Cornea 2003;22:545-8
149. Solomon A, Rosenblatt M, Li DQ, et al. Doxycycline inhibition of interleukin-1 in the cortical epithelium. Invest Ophthalmol Vis Sci 2000;41:2544-57
150. Li Y, Kuang K, Yerxa B, et al. Rabbit conjunctival epithelium transports fluid, and P2Y2(2) receptor agonists stimulate Cl(-) and fluid secretion. Am J Physiol Cell Physiol 2001;281:C595-602
151. Li DQ, Luo L, Chen Z, et al. JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp Eye Res 2006;82:588-96. Epub 2005 Oct 3b
152. Krakauer T, Buckley M. Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines. Antimicrob Agents Chemother 2003;47:3630-3
153. Voils SA, Evans ME, Lane MT, et al. Use of macrolides and tetracyclines for chronic inflammatory diseases. Ann Pharmacother 2003;39:86-94
154. Tamargo RJ, Bok RA, Brem H. Angiogenesis inhibition by minocycline. Cancer Res 1991;51:672-5
155. Sapadin AN, Fleischmajer R. Tetracyclines: Nonantibiotic properties and their clinical implications J Am Acad Dermatol 2006;54:258-65
156. Habif TP. Clinical dermatology, 4th ed. St Louis:Mosby-Year Book, 2004, pp 162-89
157. Velicer CM, Heckbert SR, Lampe JW, et al. Antibiotic use in relation to the risk of breast cancer. JAMA 2004;291:827-35
158. Velicer CM, Heckbert SR, Rutter C, et al. Association between antibiotic use prior to breast cancer diagnosis and breast tumour characteristics (United States). Cancer Causes Control (Netherlands) 2006; 17:307-13
159. Garcia Rodriguez LA , Gonzalez-Perez A. Use of antibiotics and risk of breast cancer. Am J Epidemiology 2005;161:616-9
160. Macdonald A, Feiwel M. Penoral dermatitis: aetiology and treatment with tetracycline. Br J Dermatol 1972;87:315-9 (CS3)
161. Jansen T, Plewig G. Rosacea: classification and treatment. J R Soc Med 1997;90:144-50
162. Frucht-Pery J, Chayet AS, Feldman ST, et al. The effect of doxycycline on ocular rosacea. Am J Ophthalmol 1989;107:434-5
163. Wilkin JK. Rosacea. pathophysiology and treatment. Arch Dermatol 1994;130:359-62
164. Stone DU, Chodosh J. Oral tetracyclines lot ocular rosacea: an evidence-based review of the literature. Cornea 2004;23:106-9
165. McCulley JP, Dougherty JM, Deneau DG. Classification of chronic blepharitis. Ophthalmology 1982;89:1173-80
166. Frucht-Pery J, Sagi E, Hemo I, Ever-Hadani P. Efficacy of doxycycline and tetracycline in ocular rosacea. Am J Ophthalmol 1993;116:88-92
167. Seal DV, Wright P, Picker L, et al. Placebo controlled trial of fusidic acid gel and oxytetracycline for recurrent blepharitis and rosacea. Br J Ophthalmol 1995;79-42-5
168. Hoeprich PD, Warsharuer DM. Entry of Low tetracyclines into saliva and tears. Antimicob Agents Chemother 1974;3:330-6)
169. Gulbenkian A, Myers J, Freis D. Hamster flank organ hydrolase and lipase activity. J Invest Dermatol 1980;75:289-92
170. Aronowicz JD, Shine WE, Oral D, et al. Short term oral minocycline treatment of meibomianitis. Br J Ophthalmol 2006;90:856-60
171. Yoo SE, Lee DC, Chang MH. The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction. Korean J Ophthalmol 2005;19:258-63
172. Browning DJ, Proia AD. Ocular rosacea. Surv Ophthalmol 1986;31:145-58
173. Esterly NB, Koransky JS, Furey NL, et al. Neutrophil chemotaxis in patients with acne receiving oral tetracycline therapy. Arch Dermatol 1984;120:1308-13
174. Gilbard JP. The scientific context and basis of the pharmacologic management of dry eyes. Ophthalmol Clin North Am 2005;18:475-84,v
175. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000;71(1 Suppl):3431,81,
176. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989;320:265-71
177. James MJ, Cleland LG. Dietary n-3 fatty acids and therapy for rheumatoid arthritis. Semin Arthritis Rheum 1997;27:85-97
178. Kremer JM. n-3 fatty acid supplements in rheumatoid arthritis. Am J Clin Nutr 2000;71(1 Suppl):349S-51S
179. Barabino S, Rolando M, camicione P, et al. Systemic linoleic and gammalinolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea 2003;22:97-101
180. Seedor JA, Lamberts D, Bergmann RB, Perry HD. Filamentary keratitis associated with diphenhydramine hydrochloride (Benadryl). Am J Ophthalmol 1986;101:376-7
181. Moss SE, Klein R, Klein BE. Prevalence of an risk factors for dry eye syndrome. Arch Ophthalmol 2000;118:1264-68
182. Mader TH, Stulting RD. Keratoconjunctivitis sicca caused by diphenoylate hydrochloride with atropine sulfate (Lomotil). Am J Ophthalmol 1991;111:377-8
183. Tsubota K, Nakamori K. Dry eyes and video display terminals. N Engl J Med 1993;25:328:584
184. Matoba AY, Harris DJ, Mark DB, et al. Dry eye syndrome, American Academy of Ophthalmology, 2003
185. Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: A Delphi approach to treatment recommendations. Cornea 2006;25:900-7